<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0227041.ref011">
 <label>11</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Lemoine</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Shimakawa</surname>
   <given-names>Y</given-names>
  </name>, 
  <name>
   <surname>Njie</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Taal</surname>
   <given-names>M</given-names>
  </name>, 
  <name>
   <surname>Ndow</surname>
   <given-names>G</given-names>
  </name>, 
  <name>
   <surname>Chemin</surname>
   <given-names>I</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study</article-title>. 
  <source>The Lancet Global Health</source>. 
  <year>2016</year>;
  <volume>4</volume>(
  <issue>8</issue>):
  <fpage>e559</fpage>â€“
  <lpage>e67</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S2214-109X(16)30130-9</pub-id>
  <?supplied-pmid 27443781?>
  <pub-id pub-id-type="pmid">27443781</pub-id>
 </mixed-citation>
</ref>
